AUTHORS
Giulia Schiroli, PhD, Lorenzo Tozzi, PhD2, Trine A Kristiansen, PhD3, Michael Monte4, Zsanett Jancso5, Annie Chivatakarn6, Apiwat Wangweerawong, PhD7, Andrea Calabria8, Jeff Ann, PhD9, Rahul Palchaudhuri, PhD10, Z. Jane Wang, PhD11, Luciano Apponi, PhD12, Anne Bothmer, PhD13, John P Manis, MD14, So Gun Hong, PhD15, Naoya Uchida, MD, PhD16, Robert E Donahue, DVM17, John Tisdale, MD18, Francis Pierciey, MS19, Hari Pujar, PhD20, Cecilia Cotta-Ramusino, PhD21, Michael C Holmes, PhD22
AFFILIATIONS
1 Tessera Therapeutics,, Somerville, Massachusetts, United States
2 Tessera Therapeutics,, Somerville, Massachusetts, United States
3 Tessera Therapeutics,, Somerville, Massachusetts, United States
4 Tessera Therapeutics,, Somerville, Massachusetts, United States
5 Tessera Therapeutics,, Somerville, Massachusetts, United States
6 Tessera Therapeutics,, Somerville, Massachusetts, United States
7 Tessera Therapeutics,, Somerville, Massachusetts, United States
8 Tessera Therapeutics,, Somerville, Massachusetts, United States
9 Tessera Therapeutics,, Somerville, Massachusetts, United States
10 Tessera Therapeutics,, Somerville, Massachusetts, United States
11 Tessera Therapeutics,, Somerville, Massachusetts, United States
12 Tessera Therapeutics,, Somerville, Massachusetts, United States
13 Tessera Therapeutics,, Somerville, Massachusetts, United States
14 Boston Children's Hospital,, Boston, Massachusetts, United States
15 Cellular and Molecular Therapeutics Branch, NHLBI/NIH,, Bethesda, Maryland, United States
16 Cellular and Molecular Therapeutics Branch, NHLBI/NIH,, Bethesda, Maryland, United States
17 Cellular and Molecular Therapeutics Branch, NHLBI/NIH,, Bethesda, Maryland, United States
18 Cellular and Molecular Therapeutics Branch, NHLBI/NIH,, Bethesda, Maryland, United States
19 Tessera Therapeutics,, Somerville, Massachusetts, United States
20 Tessera Therapeutics,, Somerville, Massachusetts, United States
21 Tessera Therapeutics,, Somerville, Massachusetts, United States
22 Tessera Therapeutics,, Somerville, Massachusetts, United States
ABSTRACT
Sickle cell disease (SCD) can be treated by genetic modification of autologous hematopoietic stem cells (HSCs), but current ex vivo approaches require HSC mobilization, individualized manufacturing, and conditioning before transplantation. In vivo correction of the pathogenic HBB E6V variant in long-term HSCs holds the potential to overcome these limitations and may provide a potentially safer and more scalable therapeutic approach.
Gene Writers are RNA-based gene editors designed to harness the mechanism of target-primed reverse transcription to install precise genomic changes in vivo without introducing DNA double-strand breaks, eliminating the need for viral vectors and DNA template-based editing. Here, we developed a Gene Writer comprising an engineered Cas nickase–reverse transcriptase fusion and a modified RNA template to correct the SCD-causing HBB E6V mutation directly in HSCs in vivo using HSC-targeted lipid nanoparticles.
We first defined a therapeutically relevant threshold in Townes SCD mice. HBB gene correction yields either sickle trait (HbAS) through monoallelic editing or wild-type (HbAA) through biallelic editing. Because HbAS and HbAA red blood cells have comparable lifespans, both mono- and biallelic correction events are expected to be therapeutically relevant. In competitive transplantation studies in Townes mice (HbSS), we showed that HbSS mice transplanted with either 30% HbAA or HbAS HSCs resulted in >70% red blood cell (RBC) chimerism and clinical improvements across multiple hematologic and organ pathology readouts at 6 months. These findings are consistent with available mixed bone marrow (BM) chimerism data from transplanted SCD patients and support the therapeutic relevance of both correction outcomes.
In HSCs from multiple SCD patients edited in vitro, we achieved ~70% correction of sickle alleles to wild type. Erythroid differentiation from edited cells showed 98% restoration of adult hemoglobin (HbA) by LC-MS and reduced sickling under hypoxic conditions. We next evaluated in vivo HSC editing. A single intravenous administration of Gene Writer produced greater than 50% HBB editing in phenotypic long-term HSCs (Lin–CD34+CD38–CD45RA–CD90+) in humanized NBSGW mice engrafted with cells from multiple independent healthy donors. Editing was maintained in HSCs and multilineage progeny following secondary transplantation, demonstrating modification of functional, multilineage-repopulating HSCs. In mice engrafted with SCD patient HSCs, a single dose achieved 67% HBB correction in long-term HSCs.
To directly assess disease correction in vivo, Townes HbSS mice received a single intravenous infusion of an HBB-correcting Gene Writer using a surrogate targeted HSC delivery system. Treatment achieved approximately 50% correction and produced durable improvements in hematologic parameters and organ pathology at 5 months. Gene corrected mice produced 86% HbA and showed marked improvement of anemia, reticulocytosis, together with a substantial reduction in hemolysis and red blood cell sickling.
We next assessed safety and efficacy of our in vivo HSC editing approach in non-human primates (NHP). In cynomolgus macaques (n=9), one intravenous dose was well tolerated, with no observed clinical or hematologic toxicity, and achieved a mean of 64% HBB editing in LT-HSCs, corresponding to 85% edited HSCs by single-cell analysis (n=3), reaching levels comparable to clinically approved ex vivo gene therapies. Similar efficiencies were also independently achieved in rhesus macaques (n=2), achieving a mean of 87% edited HSCs by single-cell analysis. Longitudinal follow-up of treated NHPs showed stable editing levels in HSCs for up to 19 months, with persistent contribution of edited cells across multiple hematopoietic lineages. Longitudinal analysis of edited lineages in NHPs provided insights into population kinetics after in vivo HSC editing, showing stable myeloid and erythroid output as early as 2 months after treatment.
Together, these data demonstrate efficient in vivo gene correction of human and NHP long-term HSCs at levels exceeding thresholds associated with clinical benefit, and support continued advancement of this potentially curative in vivo therapy toward clinical translation.
DISCLOSURES
Giulia Schiroli, PhD: No relevant conflicts of interest to declare.